passionate transplant nephrologist and dad of a wonderful daughter. Newbie in Cell&Gene Therapies @Bayer ex@ChariteBerlin #AAV#GCT Views here are my own
How does GLP-1 produce a CV benefit?
Reduced body weight, glycaemia,
BP, postprandial lipaemia and inflammation.
Cardioprotective mechanisms are multiple and not perfectly understood, but undeniable, as shown by SELECT study.
https://t.co/YO6QbISXYS
@sociedadSEEN@SociedadSeedo
Fresh from the press in @NatRevImmunol The 5 types of glomerulonephritis that connect pathogenesis with immunotherapy thanks to @PRomagnani@KitchingLab and Nelson Leung from Mayo https://t.co/Er9oESYWI9
Four years ago, I spent the holidays intubated in an ICU with a sudden diagnosis of cardiogenic shock due to heart failure. Today, I thank my organ donor, Lucy, for giving me this #giftoflife ♻️ through heart transplantation. #thankyou#organdonation
The last outstanding #ESGCT2022 congress is over. It was an incredible success, and nothing could have been possible without your enthusiasm, dedication and passion for science.
It was a great week to learn and to connect at #ESGCT2022#Edinburgh. Thanks the organizers @ESGCT to put an amazing program together. Safe travels for all attendees ✈️We are motivated and will facilitate #GCT for our patients💪💊 @BayerPharma
The Founder Award of #ESGCT2022 goes to Jude Samulski for his pioneering work on #AAV for #CGT. 🍾🎊Congrats Jude!!! Feel privileged and thankful to come to know him🙏@ask_bio@BayerPharma
Outstanding Achievement Award 2022 #ESGCT2022 goes to Christof von Kalle #BIH @berlinnovation and to Manfred Schmidt posthumous to help leveraging the potential of #LMPCR by enabling studies of viral integration/viral vector tracking in #GCT. Very emotional ceremony!
Presidential address given by Hildegard Büning. We are all very happy&thankful to be back at #ESGCT2022 to exchange newest data&network 🙏#GCT has a bright future with the potential to treat those pts who otherwise would never have a chance #Edinburgh#ASGCT#AAV#CRISP
APOE4 gene is linked to higher risk for #Alzheimer Mike Kaplitt @WeillCornell presented first results on gene therapy with #AAV coding for APOE2 delivered via CSF to treat APOE4 #Alzheimer pts. Promising interim results #ESGCT2022
Learned a lot about new #gene#editing strategies on #huntington disease with #AAV Kami #Cas9 and with the help of human brain atlas to predict efficiency. Great educative talk-thanks to Nicole Deglon #ESGCT2022